Details of the Drug Reposition

General Information of This Drug (ID: DMCTRLN)

Drug Name
OT-101   DMCTRLN
Drug Type
Antisense oligonucleotide

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 2/3 [1]
Pancreatic cancer DISJC981 2C10 Phase 2/3 [1]
Melanoma DIS1RRCY 2C30 Phase 2/3 [2]
Merkel cell carcinoma DISDJJ4U 2C34 Phase 2/3 [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health.